Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor

Randall E. Harris, Galal A. Alshafie, Hussein Abou-Issa, Karen Seibert

Research output: Contribution to journalArticlepeer-review

481 Scopus citations


Nonsteroidal anti-inflammatory drugs (NSAIDs) have been observed to reduce the relative risk of breast cancer. This prompted our investigation of the chemopreventive potential of celecoxib, a specific cyclooxygenase 2 blocker, against mammary carcinogenesis induced by 7,12- dimethylbenz(a)anthracene in female Sprague Dawley rats. Treatment with celecoxib was examined and compared to treatment with the general NSAID, ibuprofen, and to a control group receiving only dimethylbenz(a)anthracene. Dietary administration of celecoxib (1500 ppm) produced striking reductions in the incidence, multiplicity, and volume of breast tumors relative to the control group (68%, 86%, and 81%, respectively; P < 0.001). Ibuprofen also produced significant effects, but of lesser magnitude (40%, 52%, and 57%, respectively; P < 0.001). These results help confirm the chemopreventive activity of NSAIDs against breast cancer and provide the first evidence that a cyclooxygenase 2 blocking agent, celecoxib, possesses strong chemopreventive activity against mammary carcinogenesis.

Original languageEnglish
Pages (from-to)2101-2103
Number of pages3
JournalCancer research
Issue number8
StatePublished - Apr 15 2000


Dive into the research topics of 'Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor'. Together they form a unique fingerprint.

Cite this